Difference between revisions of "201801 Clinical Research"
Wayne Kubick (talk | contribs) |
Wayne Kubick (talk | contribs) |
||
Line 21: | Line 21: | ||
==Expected participants== | ==Expected participants== | ||
<!-- List of the individuals and/or organizations that have indicated a desire to attend the connectathon and implement this track --> | <!-- List of the individuals and/or organizations that have indicated a desire to attend the connectathon and implement this track --> | ||
+ | TransCelerate Biopharma, Inc., UCB, Pfizer, GSK, Merck, Lilly, Medidata, Oracle Health Sciences, Clinical Ink, others | ||
==Roles== | ==Roles== |
Revision as of 15:30, 17 October 2017
Track Name
Clinical Research
Submitting WG/Project/Implementer Group
Biopharma FHIR project group
Justification
This track will continue to further explore the benefits of FHIR for clinical research of new biopharmaceutical experimental treatments, and to increase visibility of FHIR within the biopharmaceutical community. This track advances the use of FHIR resources as eSource data used to pre-populate clinical research case report forms for both regulated and non-regulated clinical research. This builds on previous explorations in Connectathon 13-16. Plans for this connection include participation from at least 5 Pharmaceutical companies, Members of TransCelerate Biopharma, Inc. and technology implementers will simulate using FHIR to populate and manage clinical study databases. A set of 2-3 detailed use case scenarios will be proposed. This work will inform development of profiles and IGs to support clinical research using FHIR.
Clinical Research studies currently require the redundant entry of clinical data that already typically reside in Meaningful Use conformant EHR systems. EHR data represents original records in electronic format that can be used as eSource and directly imported into clinical research EDC databases so as to improve the quality and consistency of data between EHR and EDC systems and eliminate the need for redundant data entry. Establishing interoperability between EHR and EDC systems to streamline and modernize clinical investigations should improve data accuracy, patient safety, and clinical research efficiency. Given the extreme cost and extended time required for randomized clinical trials, it would be substantially better to utilize EHR source data to directly populate clinical trial databases wherever feasible. As stated in its May 2016 FDA draft guidance titled “Use of Electronic Health Record Data in Clinical Investigations” FDA “encourages sponsors and clinical investigators to work with the entities that control the EHRs, such as health care organizations, to use EHRs and EDC systems that are interoperable. . . Establishing interoperability between EHR and EDC systems to streamline and modernize clinical investigations should improve data accuracy, patient safety, and clinical research efficiency.”
Proposed Track Lead
See Connectathon_Track_Lead_Responsibilities Responsibilities Geoff Low (glow@mdsol.com); Trisha Simpson (trisha.simpson@ucb.com)
Expected participants
TransCelerate Biopharma, Inc., UCB, Pfizer, GSK, Merck, Lilly, Medidata, Oracle Health Sciences, Clinical Ink, others
Roles
Please include information here regarding how much advance preparation will be required if creating a client and/or server.
Role 1 Name
Scenarios
Scenario Step 1 Name
- Action:
- Precondition:
- Success Criteria:
- Bonus point: